A High-Energy Military Femoral Fracture With Multidrug-Resistant Infection: A Case Report.

Am J Case RepOct 6, 2026 (epub)
Case ReportOrthopedic SurgeryInfectious Diseases

Andris Vikmanis, Olegs Ribakovs, Anete Labalaika

✦ AI-curated · Sources linked

Case in brief

A 37-year-old military man presented with a high-energy femoral fracture complicated by a multidrug-resistant infection. After multiple debridement procedures and the use of an external fixation device, he underwent reconstruction using the Masquelet induced membrane technique. Due to complications, including limb shortening and poor bone quality, he ultimately received a cementless left hip arthroplasty, achieving a favorable functional outcome at 2-year follow-up.

Diagnostic / clinical pearl

The Masquelet induced membrane technique can be effective in managing complex bone defects, especially in cases complicated by multidrug-resistant infections.

Why it matters

This case highlights the importance of individualized antimicrobial therapy and staged orthopedic management in achieving positive outcomes in challenging trauma cases.

Source

PubMed · PMID 42837321

Published in Am J Case Rep. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.